



Regional Activity Report Cape Town, South Africa 2014





Financing (most prominent method)? In Cape Town: State for sibling donor Rest: private / medical insurance






Indications (diseases) – please list: AML, ALL, CML, NHL, MM, ALD, SAA, SS, Thal, SCID, CDA, JMML, MPS, HL, Fanconi



What is the biggest barrier to transplantation in your region? Availability of beds / facilities funded by the state.



Treatment related mortality (100 days)




- Patient Population:
- All patients

Variable	Value
Total transplants	683
Reporting centres	4
Age, median	45.9
Female / male	290 / 393
Alive / dead / missing	459 / 115 / 107




٠	Patient	Variable	Value
	Population:	All allo / first allogeneic / autologous	312 / 252 / 354
•	Allogeneic	Conditioning in allogeneic SCT Myeloablative / RIC /missing	268 / 37 / 7
		Donor type: sibling / MUD	230/ 82
		Stem cell source BM / PBPC / CBB	7 / 270 / 7





CML






 Patient Population

 First allogeneic SCT

Variable	No
All / first transplant	312 / 253
At last report: Alive / dead / no	190 / 60 / 3
Donor: sibling / MUD / mismatched family	131/69/43
Myeloablative: Y / N	195/ 23
Engrafted / Not / unknown	225 / 6 / 17
GvHD prophylaxis: Alemtuzumab / unfractionated / unknown	212/23/11
ATG: sibling / MUD	9 / 24
PBPC / BM / CB	226 / 6 / 7
GvHD: No / Yes / unknown • TcD vs. No	146 / 23 / 83 16 / 169 vs. 7 / 23 (p= 0.01)



Registry review





	Variable	Value
Patient	Patient No	30
Population Allogeneic	 Diagnosis / surviving: Acute leukaemia Aplasia / Fanconi's Myeloma Lymphoma 	3 / 1 10 / 9 10 / 6 4 / 2
as Second SCT	Donor Sibling / MUD	16 / 14
	Intensity Myeloablative / RIC	18 / 12
	TcD / no	27 / 3
	Conditioning Mel Flu Flu Cy Bu Mel Cy / Flu	13 10 7





 SASCeTS Patient Population


Autologous
 SCT

Variable	No
All patients	355
First transplants	315
Age, median	45.9
Gender: Female / Male	140 / 215
Disease status Remission / response / active	213 / 87 /15
Conditioning Myeloma AML /NHL / HL	Melphalan BEAM Bu-Mel-Cy Etopo-Cy TBI-Cy Etopo carbo











- Patient Population
- Auto SCT

Variable	Νο
Infusion complications yes / no	48
TRM Myeloma (n=213) Other (n= 139)	8 9
At last entry Alive / Died / unknown	279 / 45 / 30



Conclusions

- Young registry
- Substantial transplant activity
- Willingness to submit data
 - Information must be accurate and complete
 - Diagnosis, type of conditioning, origin of stem cells
 - Milestones are of critical value
 - Outcome
 - Date of recurrence
 - Date of death
 - Cause of death
 - ..